drugset / Trial / NCT06591091

Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression

NCT06591091

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The goal of this study is to find out if the antihistamine, clemastine, can make the white matter in the brain better in older adults with depression. The study will also determine whether this improvement can make antidepressant treatment work better, reduce depressive symptoms, and improve memory and thinking.

Timeline

Start
2025-12-10
Primary completion
2026-12
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Clemastine Small molecule 5.36 mg Oral

Indications